ABOUT US
Apollo Life Sciences is an innovative biotechnology company that has made major breakthroughs in the areas of drug delivery and expression of proteins from human cells. Apollo's combined technologies are expected to lead to more effective and lower cost therapeutics, compared to first generation protein-based drugs.
AT A GLANCE
Drug Delivery Platforms
Needle-free delivery of proteins and antibody based drugs, through two delivery systems
- oral (Oradel™)
- transdermal (TransD™)
New Therapeutics
Better protein-based treatments by using natural human proteins (hcx™)with human attachments such as glycosylation
-
click here to view our proteins range
Priority Candidates
Needle-free diabetes
- Oral insulin
Needle-free psoriasis
- Topical TNF blocker
Needle-free arthritis
- Oral & Topical TNF blocker
Drug Delivery Platforms
New Therapeutics
Priority Candidates
NEWS ROOM ASX ANNOUNCEMENT                     ASX:AOP
Bill Moss AM
Non-Executive Director and
Investor
"Apollo has a number of opportunities to grow into the future. Opportunities perhaps that are much greater than many other companies many times their size"
Click here to hear Bill Moss's view on investing in Apollo.
Professor Paul
Zimmet
AO
Head of
International Diabetes Institute, Melbourne
"The data that I have seen so far makes this one of the most forward looking and best prospects of an oral insulin"
Click here to see Paul Zimmet's view on Apollo's oral insulin
APOLLO NEWSLETTER